Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Steroids for Treatment of COPD Exacerbations

Steroids for Treatment of COPD Exacerbations Editorials represent the opinions EDITORIAL of the authors and JAMA and not those of the American Medical Association. ONLINE FIRST Less Is Clearly More 2,10 (approximately40 mg/d). However, even using this con- Don D. Sin, MD servative regimen, patients frequently experience adverse Hye Yun Park, MD, PhD effects of corticosteroids including hyperglycemia, weight gain, and insomnia. Moreover, because approximately 10% HRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) of patients experience frequent exacerbations (defined as 2 is a common, progressive lung condition, char- or more exacerbations annually), cumulative exposure to acterized by cough and dyspnea and punctuated oral corticosteroids may be substantial in some patients, lead- Cby episodes of acute exacerbations or “lung at- ing to serious long-term steroid toxicity, including weight tacks” during which these symptoms significantly in- gain, diabetes, osteoporosis, fractures, adrenal suppres- crease. These lung attacks can induce severe symptoms, caus- sion, and ocular complications. Because steroid toxicity is ing patients to seek urgent medical care and can result in dose and duration dependent, ascertainment of a minimal respiratory failure and death. In the United States, COPD effective dose to treat acute exacerbations is of critical clini- exacerbations are responsible for more than 800 000 hos- cal importance for http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Steroids for Treatment of COPD Exacerbations

JAMA , Volume 309 (21) – Jun 5, 2013

Loading next page...
 
/lp/american-medical-association/steroids-for-treatment-of-copd-exacerbations-eXOhBhECtO

References (17)

Publisher
American Medical Association
Copyright
Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2013.5644
pmid
23695265
Publisher site
See Article on Publisher Site

Abstract

Editorials represent the opinions EDITORIAL of the authors and JAMA and not those of the American Medical Association. ONLINE FIRST Less Is Clearly More 2,10 (approximately40 mg/d). However, even using this con- Don D. Sin, MD servative regimen, patients frequently experience adverse Hye Yun Park, MD, PhD effects of corticosteroids including hyperglycemia, weight gain, and insomnia. Moreover, because approximately 10% HRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) of patients experience frequent exacerbations (defined as 2 is a common, progressive lung condition, char- or more exacerbations annually), cumulative exposure to acterized by cough and dyspnea and punctuated oral corticosteroids may be substantial in some patients, lead- Cby episodes of acute exacerbations or “lung at- ing to serious long-term steroid toxicity, including weight tacks” during which these symptoms significantly in- gain, diabetes, osteoporosis, fractures, adrenal suppres- crease. These lung attacks can induce severe symptoms, caus- sion, and ocular complications. Because steroid toxicity is ing patients to seek urgent medical care and can result in dose and duration dependent, ascertainment of a minimal respiratory failure and death. In the United States, COPD effective dose to treat acute exacerbations is of critical clini- exacerbations are responsible for more than 800 000 hos- cal importance for

Journal

JAMAAmerican Medical Association

Published: Jun 5, 2013

There are no references for this article.